Non-small cell lung cancer with MET mutation: a clinical case of treatment with MET inhibitor capmatinib

• DOI: 10.21518/ms2024-545
• Publication Date: 2024-12-25T19:16:49Z
• Authors: K. V. Menshikov; A. V. Sultanbaev; Sh. I. Musin; V. S. Chalov; I. A. Menshikova; A. F. Nasretdinov; N. I. Sultanbaeva; Sh. N. Galimov
• Keywords: 0301 basic medicine; 03 medical and health sciences

The MET gene encodes cell surface receptors that have tyrosine kinase activity and mediates embryonic development, organogenesis, wound healing. Overexpression of is observed in some human cancers, including non-small lung cancer. Capmatinib a selective type Ib inhibitor MET. A total 151 patients with exon 14 skipping mutations were enrolled the GEOMETRY-mono 1 study. ORR achieved was 51% receiving second-line chemotherapy, median PFS 6.9 months. We present clinical case NSCLC treatment pretreated patient aged 50 years mutations. mutation detected by next-generation sequencing. Initially, presented metastatic disease, underwent surgical due to cancer complications. She received platinum-containing chemotherapy regimen as first-line therapy, progression, targeted therapy considered. Currently, progression-free survival 9 This observation shows efficacy capmatinib advanced Testing non-squamous for rare such MET, RET clearly needed.